Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.35 |
| ▸ | GCGR | P47871 | 4/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | FRK | P42685 | 1/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4047558 | 0.79 | DGAT1 (0.37) | SMN1; SMN2NPC1RAB9AMAPK14GCGR | |
| SCHEMBL4049587 | 0.79 | ALDH1A1 (0.41) | SMN1; SMN2POLBNPC1RAB9AKDM4E | |
| SCHEMBL17626003 | 0.79 | KDM4E (0.41) | SMN1; SMN2POLBNPC1RAB9AKDM4E | |
| SCHEMBL1119442 | 0.79 | GFER (0.46) | POLBNPC1RAB9AKDM4EMAPK14 | |
| SCHEMBL403894 | 0.78 | MTOR (0.43) | NPC1RAB9AKDM4EALDH1A1GAA | |
| SCHEMBL2651262 | 0.77 | IDO1 (0.45) | SMN1; SMN2KDM4EMAP4K4GSK3BCLK4 | |
| SCHEMBL4050105 | 0.77 | CYP2A6 (0.40) | MAPK14CLK4MAPT | |
| SCHEMBL2651782 | 0.76 | DRD1 (0.42) | NPC1RAB9AALDH1A1PKMGAA | |
| SCHEMBL6523713 | 0.76 | SCN2A (0.33) | POLBNPC1RAB9AKDM4EGFER | |
| SCHEMBL2651838 | 0.75 | RHEB (0.40) | MAPK14GCGRMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117396505-A | Methods of treating inflammation | 维鲁公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-115379835-A | Methods of treating coronavirus | 维鲁公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-112512522-A | Compounds for the treatment of triple negative breast and ovarian cancer | 田纳西大学研究基金会 | 2021-03-16 | — | — | CN | disclosed |
| CN-112437664-A | Compounds for the treatment of pancreatic cancer | 田纳西大学研究基金会 | 2021-03-02 | — | — | CN | disclosed |
| US-7589096-B2 | Azole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-15 | — | — | US | disclosed |
| EP-1566384-B1 | NOVEL AZOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2009-06-17 | — | — | EP | disclosed |
| EP-2063710-A2 | DIFLUORINATED PIPERIDINES FOR TREATMENT OF ALZHEIMER'S DISEASE AND RELATED CONDITIONS | Merck & Co., Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-2046803-A1 | IMIDAZOTHIAZOLE DERIVATIVES AS MARK INHIBITORS | Merck Sharp & Dohme Limited (GB) | 2009-04-15 | — | — | EP | disclosed |
| EP-2032138-A2 | AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK | Merck Sharp & Dohme Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| EP-2001848-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR THE TREATMENT OF DEMENTIA | MERCK SHARP & DOHME LTD. (GB) | 2008-12-17 | — | — | EP | disclosed |
| EP-1534074-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005013985-A1 | TREATMENT FOR ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| EP-1503998-A1 | HETEROARYL SUBSTITUTED SPIROCYCLIC SUFAMIDES FOR INHIBITION OF GAMMA SECRETASE | MERCK SHARP & DOHME LTD. (GB) | 2005-02-09 | — | — | EP | disclosed |
| WO-2004110375-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | MERCK & CO., INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004110368-A2 | COMBINATION THERAPY FOR THE TREATMENT OF HYPERTENSION | MERCK & CO., INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004110443-A1 | TREATMENT FOR ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004009015-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | MERCK & CO., INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2003093252-A1 | HETEROARYL SUBSTITUTED SPIROCYCLIC SULFAMIDES FOR INHIBITION OF GAMMA SECRETASE | MERCK SHARP & DOHME LIMITED (GB) | 2003-11-13 | — | — | WO | disclosed |
| EP-1204663-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001014376-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-03-01 | — | — | WO | disclosed |